MBIO - ムスタング・バイオ (Mustang Bio Inc.) ムスタング・バイオ

 MBIOのチャート


 MBIOの企業情報

symbol MBIO
会社名 Mustang Bio Inc (ムスタング・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Mustang Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology which uses the patient’s own T cells to engage and destroy specific tumors. The Company through its agreement with City of Hope National Medical Center is using three novel CAR T therapies in the development of cancer treatments including human epidermal growth factor receptor 2 CAR T technology CS1-specific CAR T technology and prostate stem cell antigen CAR T technology.   ムスタング・バイオは米国のバイオ医薬品企業。臨床段階で、免疫療法によるがん治療法の開発・商業化に従事する。患者自身の免疫システムの効果を利用し、がん細胞を排除する治療法に焦点を当てる。同社は研究開発のためライセンス供与などでテクノロジ―の所有権を取得し、最終的にはテクノロジ―を市場に投入する方向。本社所在地はニューヨーク。   Mustang Bio, Inc. ("Mustang") is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission ("SEC").
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
代表者氏名
代表者役職名
電話番号 +1 781-652-4507
設立年月日 42064
市場名 NASDAQ National Market System
ipoyear ―年
従業員数
url www.mustangbio.com
nasdaq_url https://www.nasdaq.com/symbol/mbio
adr_tso
EBITDA EBITDA(百万ドル) -34.35600
終値(lastsale) 5.25
時価総額(marketcap) 143132608.5
時価総額 時価総額(百万ドル) 126.22930
売上高 売上高(百万ドル) 0.05000
企業価値(EV) 企業価値(EV)(百万ドル) 79.48530
当期純利益 当期純利益(百万ドル) -33.91500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mustang Bio Inc revenues increased from $0K to $50K. Net loss increased 30% to $11.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.2M to $7.8M (expense) General and administrative increase of 3% to $3.8M (expense).

 MBIOのテクニカル分析


 MBIOのニュース

   Hot Stocks Highlights: Verizon Communications Inc. (NYSE:VZ), Mustang Bio, Inc. (NASDAQ:MBIO)  2021/07/20 22:23:34 Stock Equity
Verizon Communications Inc. (NYSE:VZ) with the stream of -0.45% also noticed, India Mustang Bio, Inc. (NASDAQ:MBIO) encountered a rapid change of 2.28% in the last hour of Tuesdays trading session. The post Hot Stocks Highlights: Verizon Communications Inc. (NYSE:VZ), Mustang Bio, Inc. (NASDAQ:MBIO) appeared first on Stocks Equity .
   Is The Stock A Good Investment? XpresSpa Group, Inc. (NASDAQ:XSPA), Mustang Bio, Inc. (NASDAQ:MBIO)  2021/07/12 23:12:45 Stock Equity
XpresSpa Group, Inc. (XSPA) with the stream of -4.05% also noticed, India Mustang Bio, Inc. (MBIO) encountered a rapid change of -1.44% in the last hour of Mondays trading session. The post Is The Stock A Good Investment? XpresSpa Group, Inc. (NASDAQ:XSPA), Mustang Bio, Inc. (NASDAQ:MBIO) appeared first on Stocks Equity .
   Mustang Bio (MBIO) EHA Investor Presentations - Slideshow  2021/06/18 22:11:59 Seeking Alpha
   Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive  2021/06/17 12:00:00 Wallstreet:Online
WORCESTER, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it was one of 28 recipients awarded tax incentives from the Massachusetts
   Mustang Bio to Present at the Raymond James Human Health Innovation Conference  2021/06/16 12:30:00 Benzinga
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO ), a clinical-stage biopharmaceutical company focused on translating today''s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference, taking place virtually from June 21 - 23, 2021. The company will present on Wednesday, June 23, 2021, at 8:00 a.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company''s presentation will be available on the Events page of the Investor Relations section of Mustang''s website, www.mustangbio.com , for approximately 30 days after the meeting. About Mustang Bio Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today''s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases.
   Why Mustang Bio, Phathom Pharma And More Are Moving Today  2021/02/02 16:37:39 Benzinga
Mustang Bio (NASDAQ: MBIO ) shares are trading higher after the company … Full story available on Benzinga.com
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.
   Is Mustang (MBIO) Stock a Solid Choice Right Now?  2020/05/21 12:32:00 Zacks Investment Research
Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ムスタング・バイオ MBIO Mustang Bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)